Prostaglandin Analogue Eye Drops for Glaucoma: Efficacy, Safety and First-Line Positioning

Prostaglandin analogues (PGAs) have been the global first-line medical therapy for open-angle glaucoma and ocular hypertension for two decades, and for good reason: the greatest IOP-lowering efficacy of any monotherapy class, once-daily dosing, and a side-effect profile dominated by local rather than systemic effects. The European Glaucoma Society guidelines and the American Academy of Ophthalmology Preferred Practice Pattern (Gedde et al., Ophthalmology 2021) both position PGAs as default initial therapy for most patients. In India, where generic latanoprost and travoprost are inexpensive and widely available, the class also happens to fit the economics of chronic out-of-pocket care. This article reviews the evidence, the practical differences between molecules, and the counselling that determines whether a PGA prescription succeeds.

Mechanism: Turning On the Other Drain

PGAs are prodrugs of prostaglandin F2α that bind the FP receptor in ciliary muscle and trabecular tissues, upregulating matrix metalloproteinases and remodelling the extracellular matrix of the ciliary muscle. The result is increased uveoscleral outflow — the accessory drainage pathway that conventional miotics and aqueous suppressants ignore. Because this mechanism is independent of trabecular resistance and circadian aqueous production, PGAs lower IOP consistently across the 24-hour cycle, including the nocturnal period when timolol's efficacy wanes. Peak effect develops over 8–12 weeks; judge response at month one at the earliest, not at week one.

The Efficacy Evidence

• XLT Study (Parrish et al., Am J Ophthalmol 2003): the definitive head-to-head — 411 patients randomised to latanoprost 0.005%, bimatoprost 0.03% or travoprost 0.004% once nightly. At 12 weeks, all three produced statistically indistinguishable mean IOP reductions (roughly 7–8 mmHg from baseline). Latanoprost showed the least conjunctival hyperaemia.
• van der Valk et al. (Ophthalmology 2005): meta-analysis of randomised trials across all glaucoma drug classes, confirming PGAs as the most potent monotherapy, with peak IOP reductions of 28–33%.
• Travoprost specifically achieves 25–32% mean IOP reduction from baseline in registration trials — equivalent to latanoprost in XLT, with some data suggesting better afternoon/evening IOP control and superior efficacy in Black patients.
• Switch data: patients inadequately controlled on one PGA occasionally respond to another (bimatoprost most often adds 1–2 mmHg), but intra-class switching is a second-order manoeuvre; non-response should prompt a class switch or additive therapy.

The practical translation: expect about a 30% IOP fall from monotherapy, choose the molecule on tolerability and cost, and set a target pressure before you start — not after you see the response.

Comparing the Molecules Available in India

Travotis (travoprost 0.004%) offers once-daily dosing with the 25–32% IOP reduction documented in the class literature and a BAK-free formulation advantage for patients headed toward years of daily therapy — the group in whom preservative toxicity is a genuine long-term concern.

Side Effects: Counsel or Lose the Patient

PGA side effects are local, predictable and — critically for adherence — largely cosmetic. The patient who discovers them unannounced stops the drop; the patient forewarned accepts them:

• Conjunctival hyperaemia: commonest; usually mild, often settles over months.
• Iris darkening: irreversible melanocyte stimulation, mainly in hazel/mixed-colour irides; cosmetically relevant in unilateral treatment. Document baseline iris photographs where possible.
• Periorbitopathy: deepening of the upper lid sulcus, fat atrophy, lash growth (hypertrichosis) and lid-skin pigmentation with long-term use.
• Periocular skin pigmentation: reversible on discontinuation.
• CME and uveitis caution: PGAs are associated with cystoid macular oedema and reactivation of inflammation in at-risk eyes — avoid in active uveitis and use caution in pseudophakes with open capsules or diabetic retinopathy.
• Herpes simplex keratitis: rare reactivation reported; ask about history.

Hyperaemia and Tolerability: Managing the Commonest Complaint

Conjunctival hyperaemia is the side effect patients volunteer, and it deserves more than dismissal. It reflects PGA-mediated vasodilation, is dose- and molecule-dependent (latanoprost least, bimatoprost most in the XLT dataset), typically peaks in the first weeks and often attenuates over months. Management is practical: reassure with the natural history at initiation; distinguish cosmetic redness from follicular allergy (itching, papillae — that is a stop signal, not a wait signal); review preservative load, since BAK-containing PGAs on a compromised surface compound the appearance; and switch within class before abandoning it, because hyperaemia does not always recur across molecules. A patient lost to follow-up over untreated cosmetic redness is a glaucoma outcome failure disguised as a pharmacology footnote.

Adherence: The Real Efficacy Limiter

Once-daily evening dosing is the PGA class's quiet superpower in a chronic asymptomatic disease. Support it: link instillation to an evening habit (toothbrushing), prescribe generically priced molecules the patient can sustain for decades, and check the drop technique at review — many "non-responders" are instilling onto the cheek. Digital punctal occlusion is unnecessary for efficacy but reduces systemic absorption trivially; the far more valuable minute at review is spent asking, directly and without judgement, how many doses the patient actually misses.

Storage, Handling and the Practicalities Patients Ask About

Travoprost formulations using ionic buffer systems are stable at room temperature through their in-use period, a genuine advantage in Indian conditions where refrigeration cannot be assumed and summer transport temperatures are harsh. Latanoprost historically carried refrigeration guidance, though in-use room-temperature stability for four to six weeks is documented — patients travelling or living without reliable refrigeration should be told this plainly rather than discovering a ruined bottle. Universal points apply: cap the bottle immediately, never touch the tip, discard at the labelled in-use date (typically four weeks after opening for multi-dose bottles), and carry drops in hand luggage rather than a hot car boot. These mundane details determine whether the molecule that reached the conjunctiva this morning is the one the trial measured — potency on paper means nothing after six weeks on a dashboard.

Setting the Target and Judging Response

A PGA prescription without a target pressure is half a treatment plan. Before the first bottle, document baseline IOP (ideally diurnal or at least repeated), disc and field status, and central corneal thickness, then state a target — typically 20–30% below baseline for moderate disease, deeper for advanced. At the first review (4–8 weeks), judge the response honestly:

• On target: continue; next review in 3–6 months with field and imaging surveillance on schedule.
• Partial response (15–20% fall): verify adherence and technique before adding therapy; a genuine partial responder needs a second agent or laser, not a lecture.
• Minimal response (<15% fall): true PGA non-response exists in roughly 10–15% of patients. Switch class rather than persist; aqueous suppressants or SLT are the next moves.

Selective laser trabeculoplasty deserves explicit mention here: the LiGHT trial established SLT as a safe, effective first-line alternative to drops for ocular hypertension and mild-moderate open-angle glaucoma, and in adherence-poor populations it is often the more durable strategy. A PGA-first policy and an SLT-first policy are both defensible in 2026; an unexamined reflex to drops for every patient is less so.

PGAs in the Indian Treatment Landscape

Several features of Indian glaucoma care shape PGA prescribing in practice. Presentation is late — a large fraction of Indian glaucoma is diagnosed with established field loss, so the initial target is often aggressive and monotherapy frequently insufficient from the start. Out-of-pocket payment makes the monthly bottle price a determinant of five-year persistence; generic travoprost and latanoprost have narrowed the cost gap with timolol enough to make PGA-first economically realistic for most urban patients, and increasingly for tier-2 and tier-3 towns. Screening of steroid responders matters more here than in Western datasets because over-the-counter steroid drops are so widely misused — a meaningful share of "open-angle glaucoma" in young Indian adults is steroid-induced, and the PGA works as well in those eyes while the steroid is withdrawn. Finally, angle-closure remains proportionally far more prevalent in India than in Western practice: confirm the angle is open before any PGA prescription, because uveoscleral enhancement does nothing for a pupil-block mechanism and an iridotomy is the treatment that changes that patient's trajectory.

When PGAs Are Not First Choice

• Active uveitic glaucoma — prostaglandin-mediated inflammation is the wrong tool.
• Neovascular glaucoma — limited efficacy and theoretical VEGF interaction; manage the drive.
• Angle-closure mechanisms — PGAs do not open angles; address the pupil block or plateau first.
• Pregnancy — avoid; data are limited and alternatives exist.
• Patients prioritising cosmesis (unilateral treatment, actors, public-facing professionals) — disclose iris and periorbital effects explicitly.

Adding On: Rational Combinations

When a PGA alone misses target, add a complementary mechanism: a beta-blocker or alpha-agonist for aqueous suppression. Fixed combinations (PGA-timolol) improve adherence but lock the beta-blocker contraindications into the regimen; a bedtime PGA plus a twice-daily add-on such as Brimolux-T (brimonidine-timolol) suits patients without cardiopulmonary contraindications who need dual aqueous suppression alongside outflow enhancement.

Frequently Asked Questions

Why are prostaglandin analogues first-line for glaucoma?

They deliver the greatest IOP reduction of any monotherapy (about 25–33%), work around the clock including at night, require only once-daily dosing, and have essentially no systemic side effects — advantages codified in EGS and AAO guidance.

How long does travoprost take to reach full effect?

Initial IOP fall occurs within days, but the full effect develops over 8–12 weeks as uveoscleral pathway remodelling matures. Assess response no earlier than 4 weeks, and ideally at 3 months.

Can prostaglandin eye drops change eye colour?

Yes — irreversible iris darkening occurs in a minority of patients with mixed-colour (hazel, green-brown) irides, typically over months to years. Uniformly brown irides show little visible change. Counsel before starting, especially for unilateral therapy.

What if one prostaglandin analogue does not control IOP?

Confirm adherence and technique first. Then either switch within class (occasional incremental benefit, most with bimatoprost) or — more reliably — add a second agent from a complementary class, or consider laser trabeculoplasty before committing to multi-bottle therapy.

Are prostaglandin analogues safe long term?

Yes; two decades of post-marketing data support chronic safety. Long-term issues are local and cosmetic (periorbitopathy, pigmentation) rather than systemic. Periodic review for CME risk in pseudophakic and diabetic eyes is prudent.

---

This article is for educational purposes for healthcare professionals and does not replace clinical judgement. Target pressures and agent selection must be individualised to stage of disease and patient factors.

Oculentis Medical supplies Travotis (travoprost 0.004%) for first-line glaucoma care across India. To evaluate it in your clinic, request a sample or contact our team.